# Sacituzumab tirumotecan in previously treated metastatic triple-negative breast cancer: a randomized phase 3 trial

Source: https://onco.cc/key-papers/paper-nct05347134-nat-med-2025/  
OnCo record `paper-nct05347134-nat-med-2025` (Key paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Published report from the trial registered as NCT05347134, in Nature Medicine (2025), chosen as the most cited paper whose own text cites the registry id.

## Summary

Chemotherapy remains a standard treatment option for metastatic triple-negative breast cancer (TNBC) but is associated with limited survival. Although some targeted antibody-drug conjugates have demonstrated clinical benefits and are considered standard therapy, persistent unmet medical needs remain due to varying accessibility. The OptiTROP-Breast01 phase 3 trial assessed sacituzumab tirumotecan (sac-TMT) versus chemotherapy in patients with locally recurrent or metastatic TNBC who had received two or more prior therapies, including at least one for metastatic disease. Patients were randomized to sac-TMT (n = 130) or chemotherapy (n = 133). The primary endpoint of progression-free survival (PFS) by blinded independent central review (BICR) was met based on the protocol-specified interim analysis. At final analysis, the median PFS by BICR was 6.7 (95% confidence interval (CI), 5.5-8.0) months with sac-TMT and 2.5 (95% CI, 1.7-2.7) months with chemotherapy (hazard ratio (HR), 0.32; 95% CI, 0.24-0.44; P < 0.00001). Concurrently, at the protocol-specified interim analysis for overall survival (OS), the median OS was not reached (95% CI, 11.2 months to not estimable (NE)) with sac-TMT and 9.4 (95% CI, 8.5-11.7) months with chemotherapy (HR, 0.53; 95% CI, 0.36-0.78; P = 0.0005). The percentage of patients with an objective response was 45.4% with sac-TMT and 12.0% with chemotherapy. The median duration of response was 7.1 (95% CI, 5.6-NE) months with sac-TMT and 3.0 (95% CI, 2.5-NE) months with chemotherapy. The most common treatment-related adverse event with sac-TMT was hematologic toxicity. Sac-TMT demonstrated statistically significant and clinically meaningful improvements in PFS compared to chemotherapy, with a manageable safety profile. The study findings support sac-TMT as an additional effective treatment option for pretreated metastatic TNBC. ClinicalTrials.gov identifier: NCT05347134.

Indexed on Europe PMC as PubMed record 40217078 (DOI 10.1038/s41591-025-03630-w). Its abstract cites the registry id NCT05347134, which is how it was matched to this trial; no figure has been checked by an editor.

## Fields

- Kind: Key paper
- Last checked: 2026-09-22
- Tags: europepmc-ingest
- Journal: Nature Medicine
- Year: 2025
- DOI: 10.1038/s41591-025-03630-w
- Authors: Yin Y, Fan Y, Ouyang Q, et al.
- What it means: This is the paper Europe PMC returns for registry id NCT05347134 with the most citations, so it is the natural first reading for anyone following the trial. Read the abstract above alongside the trial page and the registry entry; the record was linked automatically and its figures have not been checked by hand.
- Caveats: Matched to the trial by the registry id cited in the Europe PMC record; the summary reproduces the record's abstract and no figure has been verified against the full paper.

## Sources

- Nat Med 2025: https://doi.org/10.1038/s41591-025-03630-w
- PubMed: https://pubmed.ncbi.nlm.nih.gov/40217078/
- Europe PMC: https://europepmc.org/article/MED/40217078
- ClinicalTrials.gov NCT05347134: https://clinicaltrials.gov/study/NCT05347134

## Connected records

- trials: [SKB264 Injection vs Investigator Selected Regimens to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer](https://onco.cc/trials/nct05347134/)
- journals: [Nature Medicine](https://onco.cc/journals/nature-medicine/)
- ideas: [Efflux-agnostic therapy for mesenchymal TNBC](https://onco.cc/ideas/idea-efflux-agnostic/)

---
JSON: https://onco.cc/api/v1/entities/paper-nct05347134-nat-med-2025.json